A115180 Stock Overview
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Qurient Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,335.00 |
| 52 Week High | ₩9,276.92 |
| 52 Week Low | ₩2,361.54 |
| Beta | 0.68 |
| 1 Month Change | -2.03% |
| 3 Month Change | 1.64% |
| 1 Year Change | -52.04% |
| 3 Year Change | -80.33% |
| 5 Year Change | -74.03% |
| Change since IPO | -85.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| A115180 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 2.4% | 0.6% |
| 1Y | -52.0% | 11.1% | 6.9% |
Return vs Industry: A115180 underperformed the KR Biotechs industry which returned 11.1% over the past year.
Return vs Market: A115180 underperformed the KR Market which returned 6.9% over the past year.
Price Volatility
| A115180 volatility | |
|---|---|
| A115180 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A115180 has not had significant price volatility in the past 3 months.
Volatility Over Time: A115180's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 33 | Ki-Yean Nam | www.qurient.com |
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors.
Qurient Co., Ltd. Fundamentals Summary
| A115180 fundamental statistics | |
|---|---|
| Market cap | ₩131.94b |
| Earnings (TTM) | -₩21.12b |
| Revenue (TTM) | ₩9.03b |
14.6x
P/S Ratio-6.2x
P/E RatioIs A115180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A115180 income statement (TTM) | |
|---|---|
| Revenue | ₩9.03b |
| Cost of Revenue | ₩7.27b |
| Gross Profit | ₩1.76b |
| Other Expenses | ₩22.88b |
| Earnings | -₩21.12b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -693.79 |
| Gross Margin | 19.52% |
| Net Profit Margin | -233.80% |
| Debt/Equity Ratio | 0% |
How did A115180 perform over the long term?
See historical performance and comparison